Document is current
Any future updates will be listed below
-
Authors
Shen, Chia-I
Chao, Heng-Sheng
Shiao, Tsu-Hui
Chiang, Chi-Lu
Huang, Hsu-Ching
Luo, Yung-Hung
Chiu, Chao-Hua
Chen, Yuh-Min
-
Funding
Funding for this research was provided by:
Taipei Veterans General Hospital (V109A-003)
Ministry of Science and Technology, Taiwan (MOST 109-2314-B-075-083-MY3)
- License Information
-
More Information
Article History
Received: 6 March 2021
Accepted: 22 July 2021
First Online: 9 August 2021
Competing interests
: Yuh-Min Chen has received honoraria from Boehringer Ingelheim, Eli Lilly, Roche/Genentech/Chugai, MSD, Pfizer, Novartis, BMS, Ono Pharmaceutical, AstraZeneca, and Takeda Oncology; and served as advisor for Boehringer Ingelheim, Eli Lilly, Roche/Chugai, MSD, AstraZeneca, and Takeda Oncology. Chao-Hua Chiu has received honoraria from AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, and Roche. Chi-Lu Chiang has received honoraria from AstraZeneca, Boehringer Ingelheim, Roche, Merck Sharp & Dohme, Bristol-Myers Squibb and Ono Pharmaceutical. Other authors have nothing to disclose.
